-
1
-
-
77956535599
-
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
-
Epub 2010/05/05. doi: blood-2010-01-043737 [pii] PMID: 20439624; PubMed Central PMCID: PMC2938125
-
Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010; 116(7):1035-44. Epub 2010/05/05. doi: blood-2010-01-043737 [pii]doi: 10.1182/blood-2010-01-043737 PMID: 20439624; PubMed Central PMCID: PMC2938125.
-
(2010)
Blood
, vol.116
, Issue.7
, pp. 1035-1044
-
-
Jena, B.1
Dotti, G.2
Cooper, L.J.3
-
2
-
-
34248149835
-
Principles of adoptive T cell cancer therapy
-
Epub 2007/05/04. PMID: 17476350; PubMed Central PMCID: PMC1857246
-
June CH. Principles of adoptive T cell cancer therapy. J Clin Invest. 2007; 117(5):1204-12. Epub 2007/05/04. doi: 10.1172/JCI31446 PMID: 17476350; PubMed Central PMCID: PMC1857246.
-
(2007)
J Clin Invest
, vol.117
, Issue.5
, pp. 1204-1212
-
-
June, C.H.1
-
3
-
-
84876325876
-
Chimeric antigen receptormodified T cells for acute lymphoid leukemia
-
Epub 2013/03/27. PMID: 23527958
-
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-18. Epub 2013/03/27. doi: 10.1056/NEJMoa1215134 PMID: 23527958.
-
(2013)
N Engl J Med
, vol.368
, Issue.16
, pp. 1509-1518
-
-
Grupp, S.A.1
Kalos, M.2
Barrett, D.3
Aplenc, R.4
Porter, D.L.5
Rheingold, S.R.6
-
4
-
-
80455179612
-
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
-
Epub 2011/08/19. PMID: 21849486; PubMed Central PMCID: PMC3208293
-
Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118(18):4817-28. Epub 2011/08/19. doi: 10.1182/blood-2011-04-348540 PMID: 21849486; PubMed Central PMCID: PMC3208293.
-
(2011)
Blood
, vol.118
, Issue.18
, pp. 4817-4828
-
-
Brentjens, R.J.1
Riviere, I.2
Park, J.H.3
Davila, M.L.4
Wang, X.5
Stefanski, J.6
-
5
-
-
84863337890
-
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
-
Epub 2011/12/14. PMID: 22160384; PubMed Central PMCID: PMC3327450
-
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119(12):2709-20. Epub 2011/12/14. doi: 10.1182/blood-2011-10-384388 PMID: 22160384; PubMed Central PMCID: PMC3327450.
-
(2012)
Blood
, vol.119
, Issue.12
, pp. 2709-2720
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Feldman, S.A.3
Wilson, W.H.4
Spaner, D.E.5
Maric, I.6
-
6
-
-
80051775476
-
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
-
Epub 2011/08/13. doi: 3/95/95ra73 [pii]. PMID: 21832238
-
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95: ):95ra73. Epub 2011/08/13. doi: 3/95/95ra73 [pii]doi: 10.1126/scitranslmed.3002842 PMID: 21832238.
-
(2011)
Sci Transl Med
, vol.3
, Issue.95
, pp. 95ra73
-
-
Kalos, M.1
Levine, B.L.2
Porter, D.L.3
Katz, S.4
Grupp, S.A.5
Bagg, A.6
-
7
-
-
80051720194
-
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
-
Epub 2011/08/13. PMID: 21830940
-
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. Epub 2011/08/13. doi: 10.1056/NEJMoa1103849 PMID: 21830940.
-
(2011)
N Engl J Med
, vol.365
, Issue.8
, pp. 725-733
-
-
Porter, D.L.1
Levine, B.L.2
Kalos, M.3
Bagg, A.4
June, C.H.5
-
8
-
-
84887821770
-
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study
-
Epub 2013/09/14. PMID: 24030379; PubMed Central PMCID: PMC3811171
-
Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013; 122(17):2965-73. Epub 2013/09/14. doi: 10.1182/blood-2013-06-506741 PMID: 24030379; PubMed Central PMCID: PMC3811171.
-
(2013)
Blood
, vol.122
, Issue.17
, pp. 2965-2973
-
-
Cruz, C.R.1
Micklethwaite, K.P.2
Savoldo, B.3
Ramos, C.A.4
Lam, S.5
Ku, S.6
-
9
-
-
84908073316
-
Chimeric antigen receptor T cells for sustained remissions in leukemia
-
Epub 2014/10/16. PMID: 25317870
-
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. Epub 2014/10/16. doi: 10.1056/NEJMoa1407222 PMID: 25317870.
-
(2014)
N Engl J Med
, vol.371
, Issue.16
, pp. 1507-1517
-
-
Maude, S.L.1
Frey, N.2
Shaw, P.A.3
Aplenc, R.4
Barrett, D.M.5
Bunin, N.J.6
-
10
-
-
84923019006
-
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial
-
PMID: 25319501
-
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517-28. doi: 10.1016/S0140-6736(14) 61403-3 PMID: 25319501.
-
(2015)
Lancet
, vol.385
, Issue.9967
, pp. 517-528
-
-
Lee, D.W.1
Kochenderfer, J.N.2
Stetler-Stevenson, M.3
Cui, Y.K.4
Delbrook, C.5
Feldman, S.A.6
-
11
-
-
20444499355
-
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
-
Epub 2005/06/03. PMID: 15931392; PubMed Central PMCID: PMC1137001
-
Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. Epub 2005/06/03. doi: 10.1172/JCI24480 PMID: 15931392; PubMed Central PMCID: PMC1137001.
-
(2005)
J Clin Invest
, vol.115
, Issue.6
, pp. 1616-1626
-
-
Gattinoni, L.1
Klebanoff, C.A.2
Palmer, D.C.3
Wrzesinski, C.4
Kerstann, K.5
Yu, Z.6
-
12
-
-
84904394259
-
Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells
-
Epub 2014/07/19. PMID: 25035956
-
Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014; 41(1):116-26. Epub 2014/07/19. doi: 10.1016/j.immuni.2014.05.018 PMID: 25035956.
-
(2014)
Immunity
, vol.41
, Issue.1
, pp. 116-126
-
-
Graef, P.1
Buchholz, V.R.2
Stemberger, C.3
Flossdorf, M.4
Henkel, L.5
Schiemann, M.6
-
13
-
-
25444448741
-
Clinical uses of intravenous immunoglobulin
-
PMID: 16178850; PubMed Central PMCID: PMC1809480
-
Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005; 142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x PMID: 16178850; PubMed Central PMCID: PMC1809480.
-
(2005)
Clin Exp Immunol
, vol.142
, Issue.1
, pp. 1-11
-
-
Jolles, S.1
Sewell, W.A.2
Misbah, S.A.3
-
14
-
-
77950480974
-
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase i clinical trial
-
Epub 2010/04/02. PMID: 20357779; PubMed Central PMCID: PMC2862525
-
Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010; 18(4):666-8. Epub 2010/04/02. doi: 10.1038/mt.2010.31 PMID: 20357779; PubMed Central PMCID: PMC2862525.
-
(2010)
Mol Ther
, vol.18
, Issue.4
, pp. 666-668
-
-
Brentjens, R.1
Yeh, R.2
Bernal, Y.3
Riviere, I.4
Sadelain, M.5
-
15
-
-
0035192873
-
Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: Redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases
-
Epub 2001/11/20. PMID: 11713269; PubMed Central PMCID: PMC99997
-
Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, Yoda A, et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol. 2001; 21(24):8329-35. Epub 2001/11/20. doi: 10.1128/MCB.21.24.8329-8335.2001 PMID: 11713269; PubMed Central PMCID: PMC99997.
-
(2001)
Mol Cell Biol
, vol.21
, Issue.24
, pp. 8329-8335
-
-
Nomi, M.1
Oishi, I.2
Kani, S.3
Suzuki, H.4
Matsuda, T.5
Yoda, A.6
-
16
-
-
38949156617
-
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
-
Epub 2008/01/29. PMID: 18223214
-
Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008; 14(2):396-404. Epub 2008/01/29. doi: 10.1158/1078-0432.CCR-07-1823 PMID: 18223214.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.2
, pp. 396-404
-
-
Baskar, S.1
Kwong, K.Y.2
Hofer, T.3
Levy, J.M.4
Kennedy, M.G.5
Lee, E.6
-
17
-
-
47249140824
-
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
-
Epub 2008/06/12. PMID: 18546292
-
Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008; 123(5):1190-5. Epub 2008/06/12. doi: 10.1002/ijc.23587 PMID: 18546292.
-
(2008)
Int J Cancer
, vol.123
, Issue.5
, pp. 1190-1195
-
-
Daneshmanesh, A.H.1
Mikaelsson, E.2
Jeddi-Tehrani, M.3
Bayat, A.A.4
Ghods, R.5
Ostadkarampour, M.6
-
18
-
-
42949121156
-
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a
-
Epub 2008/02/22. PMID: 18287027; PubMed Central PMCID: PMC2268582
-
Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008; 105(8):3047-52. Epub 2008/02/22. doi: 10.1073/pnas.0712148105 PMID: 18287027; PubMed Central PMCID: PMC2268582.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.8
, pp. 3047-3052
-
-
Fukuda, T.1
Chen, L.2
Endo, T.3
Tang, L.4
Lu, D.5
Castro, J.E.6
-
19
-
-
84863251015
-
ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth
-
Epub 2012/03/10. PMID: 22403610; PubMed Central PMCID: PMC3293865
-
Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7(3):e31127. Epub 2012/03/10. doi: 10.1371/journal.pone.0031127 PMID: 22403610; PubMed Central PMCID: PMC3293865.
-
(2012)
PLoS One
, vol.7
, Issue.3
-
-
Zhang, S.1
Chen, L.2
Cui, B.3
Chuang, H.Y.4
Yu, J.5
Wang-Rodriguez, J.6
-
20
-
-
84869166013
-
The onco-embryonic antigen ROR1 is expressed by a variety of human cancers
-
Epub 2012/10/09. PMID: 23041612; PubMed Central PMCID: PMC3509760
-
Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012; 181(6):1903-10. Epub 2012/10/09. doi: 10.1016/j.ajpath.2012.08.024 PMID: 23041612; PubMed Central PMCID: PMC3509760.
-
(2012)
Am J Pathol
, vol.181
, Issue.6
, pp. 1903-1910
-
-
Zhang, S.1
Chen, L.2
Wang-Rodriguez, J.3
Zhang, L.4
Cui, B.5
Frankel, W.6
-
21
-
-
84869065974
-
ROR1 and ROR2 in Human 1Malignancies: Potentials for Targeted Therapy
-
Epub 2012/06/02. PMID: 22655270; PubMed Central PMCID: PMC3356025
-
Rebagay G, Yan S, Liu C, Cheung NK. ROR1 and ROR2 in Human 1Malignancies: Potentials for Targeted Therapy. Front Oncol. 2012; 2:34. Epub 2012/06/02. doi: 10.3389/fonc.2012.00034 PMID: 22655270; PubMed Central PMCID: PMC3356025.
-
(2012)
Front Oncol
, vol.2
, pp. 34
-
-
Rebagay, G.1
Yan, S.2
Liu, C.3
Cheung, N.K.4
-
22
-
-
84914140232
-
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy
-
PMID: 25411317; PubMed Central PMCID: PMC4260559
-
Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014; 111 (48):17266-71. doi: 10.1073/pnas.1419599111 PMID: 25411317; PubMed Central PMCID: PMC4260559.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, Issue.48
, pp. 17266-17271
-
-
Zhang, S.1
Cui, B.2
Lai, H.3
Liu, G.4
Ghia, E.M.5
Widhopf, G.F.6
-
23
-
-
84871429839
-
Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies
-
Epub 2013/01/04. PMID: 23285131; PubMed Central PMCID: PMC3527582
-
Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, et al. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One. 2012; 7(12):e52655. Epub 2013/01/04. doi: 10.1371/journal.pone.0052655 PMID: 23285131; PubMed Central PMCID: PMC3527582.
-
(2012)
PLoS One
, vol.7
, Issue.12
-
-
Dave, H.1
Anver, M.R.2
Butcher, D.O.3
Brown, P.4
Khan, J.5
Wayne, A.S.6
-
24
-
-
80052079318
-
ROR1 is expressed on hematogones (nonneoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia
-
Epub 2011/08/05. PMID: 21813176; PubMed Central PMCID: PMC3163753
-
Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (nonneoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011; 35(10):1390-4. Epub 2011/08/05. doi: 10.1016/j.leukres.2011.06.021 PMID: 21813176; PubMed Central PMCID: PMC3163753.
-
(2011)
Leuk Res
, vol.35
, Issue.10
, pp. 1390-1394
-
-
Broome, H.E.1
Rassenti, L.Z.2
Wang, H.Y.3
Meyer, L.M.4
Kipps, T.J.5
-
25
-
-
84962304846
-
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells
-
PMID: 25355068; PubMed Central PMCID: PMC4324006
-
Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res. 2015; 3 (2):206-16. doi: 10.1158/2326-6066.CIR-14-0163 PMID: 25355068; PubMed Central PMCID: PMC4324006.
-
(2015)
Cancer Immunol Res.
, vol.3
, Issue.2
, pp. 206-216
-
-
Berger, C.1
Sommermeyer, D.2
Hudecek, M.3
Berger, M.4
Balakrishnan, A.5
Paszkiewicz, P.J.6
-
26
-
-
77950525914
-
A transposon and transposase system for human application
-
Epub 2010/01/28. doi: mt20102 [pii]. PMID: 20104209; PubMed Central PMCID: PMC2862530
-
Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010; 18(4):674-83. Epub 2010/01/28. doi: mt20102 [pii]doi: 10.1038/mt.2010.2 PMID: 20104209; PubMed Central PMCID: PMC2862530.
-
(2010)
Mol Ther
, vol.18
, Issue.4
, pp. 674-683
-
-
Hackett, P.B.1
Largaespada, D.A.2
Cooper, L.J.3
-
27
-
-
84875138464
-
Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy
-
Epub 2013/01/15. PMID: 23313630; PubMed Central PMCID: PMC3602164
-
Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013; 161(4):265-83. Epub 2013/01/15. doi: 10.1016/j. trsl.2012.12.005 PMID: 23313630; PubMed Central PMCID: PMC3602164.
-
(2013)
Transl Res
, vol.161
, Issue.4
, pp. 265-283
-
-
Hackett, P.B.1
Largaespada, D.A.2
Switzer, K.C.3
Cooper, L.J.4
-
28
-
-
84877626190
-
Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood
-
Epub 2013/02/15. PMID: 23407473; PubMed Central PMCID: PMC3596954
-
Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, et al. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013;(72: ):e50070. Epub 2013/02/15. doi: 10.3791/50070 PMID: 23407473; PubMed Central PMCID: PMC3596954.
-
(2013)
J Vis Exp
, Issue.72
-
-
Huls, M.H.1
Figliola, M.J.2
Dawson, M.J.3
Olivares, S.4
Kebriaei, P.5
Shpall, E.J.6
-
29
-
-
84873987094
-
Sleeping beauty system to redirect T-cell specificity for human applications
-
Epub 2013/02/05. PMID: 23377665; PubMed Central PMCID: PMC3568214
-
Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013; 36(2):112-23. Epub 2013/02/05. doi: 10.1097/CJI.0b013e3182811ce9 PMID: 23377665; PubMed Central PMCID: PMC3568214.
-
(2013)
J Immunother
, vol.36
, Issue.2
, pp. 112-123
-
-
Maiti, S.N.1
Huls, H.2
Singh, H.3
Dawson, M.4
Figliola, M.5
Olivares, S.6
-
30
-
-
84878547375
-
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells
-
Epub 2013/06/07. PMID: 23741305; PubMed Central PMCID: PMC3669363
-
Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS One. 2013; 8(5):e64138. Epub 2013/06/07. doi: 10.1371/journal.pone.0064138 PMID: 23741305; PubMed Central PMCID: PMC3669363.
-
(2013)
PLoS One
, vol.8
, Issue.5
-
-
Singh, H.1
Figliola, M.J.2
Dawson, M.J.3
Olivares, S.4
Zhang, L.5
Yang, G.6
-
31
-
-
84890209444
-
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19
-
Epub 2013/12/18. PMID: 24329797
-
Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014; 257(1):181-90. Epub 2013/12/18. doi: 10.1111/imr.12137 PMID: 24329797.
-
(2014)
Immunol Rev
, vol.257
, Issue.1
, pp. 181-190
-
-
Singh, H.1
Huls, H.2
Kebriaei, P.3
Cooper, L.J.4
-
32
-
-
79956149133
-
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of b-lineage malignancies
-
Epub 2011/05/12. doi: 0008-5472.CAN-10-3843 [pii]. PMID: 21558388; PubMed Central PMCID: PMC3096697
-
Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Res. 2011; 71(10):3516-27. Epub 2011/05/12. doi: 0008-5472.CAN-10-3843 [pii]doi: 10.1158/0008-5472.CAN-10-3843 PMID: 21558388; PubMed Central PMCID: PMC3096697.
-
(2011)
Cancer Res
, vol.71
, Issue.10
, pp. 3516-3527
-
-
Singh, H.1
Figliola, M.J.2
Dawson, M.J.3
Huls, H.4
Olivares, S.5
Switzer, K.6
-
33
-
-
42349088534
-
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system
-
Epub 2008/04/17. doi: 68/8/2961 [pii]. PMID: 18413766; PubMed Central PMCID: PMC2424272
-
Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008; 68(8):2961-71. Epub 2008/04/17. doi: 68/8/2961 [pii]doi: 10.1158/0008-5472.CAN-07-5600 PMID: 18413766; PubMed Central PMCID: PMC2424272.
-
(2008)
Cancer Res
, vol.68
, Issue.8
, pp. 2961-2971
-
-
Singh, H.1
Manuri, P.R.2
Olivares, S.3
Dara, N.4
Dawson, M.J.5
Huls, H.6
-
34
-
-
84869049935
-
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia
-
Epub 2012/11/17. PMID: 23153538; PubMed Central PMCID: PMC3500515
-
Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012; 22(5):656-67. Epub 2012/11/17. doi: 10.1016/j.ccr.2012.08.027 PMID: 23153538; PubMed Central PMCID: PMC3500515.
-
(2012)
Cancer Cell
, vol.22
, Issue.5
, pp. 656-667
-
-
Bicocca, V.T.1
Chang, B.H.2
Masouleh, B.K.3
Muschen, M.4
Loriaux, M.M.5
Druker, B.J.6
-
35
-
-
34247212403
-
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules
-
Epub 2007/03/22. PMID: 17375070
-
Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007; 15 (5):981-8. Epub 2007/03/22. doi: 10.1038/mt.sj.6300134 PMID: 17375070.
-
(2007)
Mol Ther
, vol.15
, Issue.5
, pp. 981-988
-
-
Suhoski, M.M.1
Golovina, T.N.2
Aqui, N.A.3
Tai, V.C.4
Varela-Rohena, A.5
Milone, M.C.6
-
36
-
-
84859768513
-
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy
-
Epub 2012/02/23. PMID: 22355761; PubMed Central PMCID: PMC3278154
-
O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012; 2:249. Epub 2012/02/23. doi: 10.1038/srep00249 PMID: 22355761; PubMed Central PMCID: PMC3278154.
-
(2012)
Sci Rep
, vol.2
, pp. 249
-
-
O'Connor, C.M.1
Sheppard, S.2
Hartline, C.A.3
Huls, H.4
Johnson, M.5
Palla, S.L.6
-
37
-
-
84907491837
-
Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies
-
PMID: 24833662; PubMed Central PMCID: PMC4233015
-
Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014; 20 (22):5708-19. doi: 10.1158/1078-0432.CCR-13-3451 PMID: 24833662; PubMed Central PMCID: PMC4233015.
-
(2014)
Clin Cancer Res
, vol.20
, Issue.22
, pp. 5708-5719
-
-
Deniger, D.C.1
Maiti, S.N.2
Mi, T.3
Switzer, K.C.4
Ramachandran, V.5
Hurton, L.V.6
-
38
-
-
84875226632
-
Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor
-
Epub 2013/01/09. PMID: 23295945; PubMed Central PMCID: PMC3589159
-
Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013; 21(3):638-47. Epub 2013/01/09. doi: 10.1038/mt.2012.267 PMID: 23295945; PubMed Central PMCID: PMC3589159.
-
(2013)
Mol Ther
, vol.21
, Issue.3
, pp. 638-647
-
-
Deniger, D.C.1
Switzer, K.2
Mi, T.3
Maiti, S.4
Hurton, L.5
Singh, H.6
-
39
-
-
78649461928
-
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
-
Epub 2010/08/13. PMID: 20702778; PubMed Central PMCID: PMC2996114
-
Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. Epub 2010/08/13. doi: 10.1182/blood-2010-05-283309 PMID: 20702778; PubMed Central PMCID: PMC2996114.
-
(2010)
Blood
, vol.116
, Issue.22
, pp. 4532-4541
-
-
Hudecek, M.1
Schmitt, T.M.2
Baskar, S.3
Lupo-Stanghellini, M.T.4
Nishida, T.5
Yamamoto, T.N.6
-
40
-
-
84861674447
-
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies
-
Epub 2011/11/24. PMID: 22107246; PubMed Central PMCID: PMC3360496
-
Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012; 23(5):444-50. Epub 2011/11/24. doi: 10.1089/hum.2011.167 PMID: 22107246; PubMed Central PMCID: PMC3360496.
-
(2012)
Hum Gene Ther
, vol.23
, Issue.5
, pp. 444-450
-
-
Kebriaei, P.1
Huls, H.2
Jena, B.3
Munsell, M.4
Jackson, R.5
Lee, D.A.6
-
41
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Epub 2011/04/19. PMID: 21498393; PubMed Central PMCID: PMC3131487
-
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17(13):4550-7. Epub 2011/04/19. doi: 10.1158/1078-0432.CCR-11-0116 PMID: 21498393; PubMed Central PMCID: PMC3131487.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.13
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
-
42
-
-
80052682032
-
Reversible senescence in human CD4+CD45RA+CD27- memory T cells
-
Epub 2011/07/27. PMID: 21788446
-
Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, et al. Reversible senescence in human CD4+CD45RA+CD27- memory T cells. J Immunol. 2011; 187(5):2093-100. Epub 2011/07/27. doi: 10.4049/jimmunol.1100978 PMID: 21788446.
-
(2011)
J Immunol
, vol.187
, Issue.5
, pp. 2093-2100
-
-
Di Mitri, D.1
Azevedo, R.I.2
Henson, S.M.3
Libri, V.4
Riddell, N.E.5
Macaulay, R.6
-
43
-
-
33745083070
-
CD8+ T-cell memory in tumor immunology and immunotherapy
-
Epub 2006/07/11. PMID: 16824130; PubMed Central PMCID: PMC1501075
-
Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006; 211:214-24. Epub 2006/07/11. doi: 10.1111/j.0105-2896.2006.00391.x PMID: 16824130; PubMed Central PMCID: PMC1501075.
-
(2006)
Immunol Rev
, vol.211
, pp. 214-224
-
-
Klebanoff, C.A.1
Gattinoni, L.2
Restifo, N.P.3
-
44
-
-
55749089404
-
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer
-
Epub 2008/09/17. PMID: 18794521; PubMed Central PMCID: PMC2567214
-
Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008; 105(38):14342-6. Epub 2008/09/17. doi: 10.1073/pnas.0804105105 PMID: 18794521; PubMed Central PMCID: PMC2567214.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.38
, pp. 14342-14346
-
-
Rabinovich, B.A.1
Ye, Y.2
Etto, T.3
Chen, J.Q.4
Levitsky, H.I.5
Overwijk, W.W.6
-
45
-
-
71649100833
-
Trans-presentation: A novel mechanism regulating IL-15 delivery and responses
-
Epub 2009/10/13. PMID: 19818367; PubMed Central PMCID: PMC2808451
-
Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett. 2010; 127(2):85-92. Epub 2009/10/13. doi: 10.1016/j.imlet.2009.09.009 PMID: 19818367; PubMed Central PMCID: PMC2808451.
-
(2010)
Immunol Lett
, vol.127
, Issue.2
, pp. 85-92
-
-
Stonier, S.W.1
Schluns, K.S.2
-
46
-
-
58149390259
-
Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation
-
Epub 2008/09/25. PMID: 18812469; PubMed Central PMCID: PMC2597127
-
Stonier SW, Ma LJ, Castillo EF, Schluns KS. Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood. 2008; 112(12):4546-54. Epub 2008/09/25. doi: 10.1182/blood-2008-05-156307 PMID: 18812469; PubMed Central PMCID: PMC2597127.
-
(2008)
Blood
, vol.112
, Issue.12
, pp. 4546-4554
-
-
Stonier, S.W.1
Ma, L.J.2
Castillo, E.F.3
Schluns, K.S.4
-
47
-
-
77950953208
-
PiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies
-
Epub 2009/11/13. PMID: 19905893; PubMed Central PMCID: PMC2938363
-
Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010; 21(4):427-37. Epub 2009/11/13. doi: 10.1089/hum.2009.114 PMID: 19905893; PubMed Central PMCID: PMC2938363.
-
(2010)
Hum Gene Ther
, vol.21
, Issue.4
, pp. 427-437
-
-
Manuri, P.V.1
Wilson, M.H.2
Maiti, S.N.3
Mi, T.4
Singh, H.5
Olivares, S.6
-
48
-
-
80053997259
-
A human memory T cell subset with stem cell-like properties
-
Epub 2011/09/20. PMID: 21926977; PubMed Central PMCID: PMC3192229
-
Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011; 17(10):1290-7. Epub 2011/09/20. doi: 10.1038/nm.2446 PMID: 21926977; PubMed Central PMCID: PMC3192229.
-
(2011)
Nat Med
, vol.17
, Issue.10
, pp. 1290-1297
-
-
Gattinoni, L.1
Lugli, E.2
Ji, Y.3
Pos, Z.4
Paulos, C.M.5
Quigley, M.F.6
-
49
-
-
84953344459
-
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity
-
PMID: 25212991
-
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015; 3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127 PMID: 25212991.
-
(2015)
Cancer Immunol Res
, vol.3
, Issue.2
, pp. 125-135
-
-
Hudecek, M.1
Sommermeyer, D.2
Kosasih, P.L.3
Silva-Benedict, A.4
Liu, L.5
Rader, C.6
-
50
-
-
84879480191
-
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
-
PMID: 23620405; PubMed Central PMCID: PMC3804130
-
Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013; 19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330 PMID: 23620405; PubMed Central PMCID: PMC3804130.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.12
, pp. 3153-3164
-
-
Hudecek, M.1
Lupo-Stanghellini, M.T.2
Kosasih, P.L.3
Sommermeyer, D.4
Jensen, M.C.5
Rader, C.6
-
51
-
-
78549278144
-
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
-
Epub 2010/07/30. doi: blood-2010-04-281931 [pii]. PMID: 20668228; PubMed Central PMCID: PMC2993617
-
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-102. Epub 2010/07/30. doi: blood-2010-04-281931 [pii]doi: 10.1182/blood-2010-04-281931 PMID: 20668228; PubMed Central PMCID: PMC2993617.
-
(2010)
Blood
, vol.116
, Issue.20
, pp. 4099-4102
-
-
Kochenderfer, J.N.1
Wilson, W.H.2
Janik, J.E.3
Dudley, M.E.4
Stetler-Stevenson, M.5
Feldman, S.A.6
-
52
-
-
19344365874
-
An inducible caspase 9 safety switch for T-cell therapy
-
Epub 2005/02/25. PMID: 15728125; PubMed Central PMCID: PMC1895037
-
Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005; 105(11):4247-54. Epub 2005/02/25. doi: 10.1182/blood-2004-11-4564 PMID: 15728125; PubMed Central PMCID: PMC1895037.
-
(2005)
Blood
, vol.105
, Issue.11
, pp. 4247-4254
-
-
Straathof, K.C.1
Pule, M.A.2
Yotnda, P.3
Dotti, G.4
Vanin, E.F.5
Brenner, M.K.6
|